NuCana plc NCNA
Biotechnology: Pharmaceutical Preparations · IPO 2017 · data as of November 13, 2026
NuCana plc (NCNA) is a healthcare company listed in the US with a market value of about $4M.
Its overall Stock Analiz score is 0.4 out of 5 (weak). The strongest part is financial health (2/5); the weakest is value (0/5).
Key numbers: a 5-year average ROIC of -148%.
About NuCana
NuCana is listed in the US and classified in biotechnology: pharmaceutical preparations, IPO year 2017. It was profitable in 0 of the last 10 years in our data.
Score: 0.4 / 5
Checks passed
- More cash than debt, or low debt to equity
- Liabilities below 60% of assets
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — | — | — |
| Net income | -$40M | -$24M | -$35M | -$39M | -$55M | -$42M | -$28M | -$18M | -$31M | -$7M |
| Free cash flow | -$10M | -$24M | -$34M | -$28M | -$32M | -$30M | -$32M | -$16M | -$12M | -$11M |
| EPS (diluted) | $-9.50 | $-5.72 | $-8.44 | $-9.25 | $-13.13 | $-10.06 | $-6.79 | $-4.26 | $-7.50 | $-1.79 |
| Net margin | — | — | — | — | — | — | — | — | — | — |
| ROIC | -79.5% | -324.1% | -190.0% | -84.6% | -62.0% | -31.1% | -35.1% | -18.0% | -24.9% | -24.8% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
Frequently asked questions
Does NuCana pay a dividend?
Not currently.
Is NuCana a good stock to buy?
We do not give buy or sell advice. NuCana scores 0.4 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.